Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT05261490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Study identification
- NCT ID
- NCT05261490
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- maplirpacept (PF-07901801) Drug
- Pegylated Liposomal Doxorubicin (PLD) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2022
- Primary completion
- Oct 10, 2023
- Completion
- Feb 14, 2024
- Last update posted
- Nov 18, 2024
2022 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
| Orlando Health Cancer Institute Gynecologic Cancer Center | Orlando | Florida | 32806 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Michigan Healthcare Professionals PC | Dearborn | Michigan | 48126 | — |
| Michigan Healthcare Professionals PC | Farmington Hills | Michigan | 48334 | — |
| Michigan Healthcare Professionals PC | Royal Oak | Michigan | 48073 | — |
| Michigan Healthcare Professionals PC | Sterling Heights | Michigan | 48314 | — |
| Cleveland Clinic taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic Hillcrest Hospital | Mayfield Heights | Ohio | 44124 | — |
| Oklahoma Cancer Specialist and Research Institute. LLC | Tulsa | Oklahoma | 74146 | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Hillman Cancer Center-Investigational Drug Services | Pittsburgh | Pennsylvania | 15232 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| oncology Consultants, P.A. | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05261490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2024 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05261490 live on ClinicalTrials.gov.